Does growth hormone substitution improve cardiovascular protection in adult patients with growth hormone deficiency?
Current evidence is insufficient to recommend growth hormone substitution for cardiovascular protection in patients with growth hormone deficiency.
The GHD population may be considered at high cardiovascular risk, and GH substitution may be expected to bring an added value to patients with hypopituitarism in terms of cardiovascular protection. However, there is too limited evidence (rarely coming from randomized and controlled studies) to recommend GH treatment based on the cardiovascular status of the patients.
Gazzaruso et al. (Tue,) studied this question.